MedTrace Logo

Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation for Two More Years (LUTEGA 2)

NCT01648660 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-01-10

No results posted yet for this study

Summary

The primary objective of LUTEGA 2 is it to determine the long term effect (about 2 more years after LUTEGA 1, NCT00763659) of the supplementation with a fixed combination of lutein/zeaxanthin and omega-3- fatty acids in two different dosages on the optical density (OD) of macular pigment in patients with non- exudative age related maculopathy. The dosage groups are crossed after LUTEGA 1.

Conditions

  • Age Related Maculopathy

Interventions

DIETARY_SUPPLEMENT

Lutein/ Zeaxanthin + Omega- 3- Fatty Acids

capsule with Lutein, Zeaxanthin, Omega-3-FA for two years

Sponsors & Collaborators

  • University of Jena

    lead OTHER

Principal Investigators

  • Jürgen Strobel, MD · University Hospital Jena

  • Jens Dawczynski, MD · University of Leipzig

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-12-31
Completion
2012-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01648660 on ClinicalTrials.gov